Gene therapy for sickle cell disease: An updateSelami Demirci, John F. Tisdale, Naoya Uchida|Cytotherapy|2018Cited by 114
Bone marrow characterization in sickle cell disease: inflammation and stress erythropoiesis lead to suboptimal CD34 recoveryAlexis Leonard, John F. Tisdale, Aylin Bonifacino et al.|British Journal of Haematology|2019Cited by 75
BCL11A enhancer–edited hematopoietic stem cells persist in rhesus monkeys without toxicitySelami Demirci, John F. Tisdale, Nathaniel S. Linde et al.|Journal of Clinical Investigation|2020Cited by 67
CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and ChallengesSelami Demirci, John F. Tisdale, Alexis Leonard et al.|Advances in experimental medicine and biology|2019Cited by 62
Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell diseaseNaoya Uchida, John F. Tisdale, Claire Drysdale et al.|Molecular Therapy — Methods & Clinical Development|2021Cited by 51